Oric Pharmaceuticals/$ORIC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Ticker
$ORIC
Sector
Primary listing
Employees
128
Headquarters
Website
ORIC Metrics
BasicAdvanced
$994M
-
-$1.89
1.69
-
Price and volume
Market cap
$994M
Beta
1.69
52-week high
$14.67
52-week low
$3.90
Average daily volume
1.1M
Financial strength
Current ratio
16.129
Quick ratio
15.652
Long term debt to equity
1.485
Total debt to equity
1.485
Profitability
EBITDA (TTM)
-148.484
Management effectiveness
Return on assets (TTM)
-27.69%
Return on equity (TTM)
-43.82%
Valuation
Price to book
2.72
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-6.123
Free cash flow yield (TTM)
-16.33%
Free cash flow per share (TTM)
-1.671
Growth
Earnings per share change (TTM)
7.82%
3-year earnings per share growth (CAGR)
-4.22%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Bulls say / Bears say
Ongoing Phase 1b data for ORIC-944 showed a 59% confirmed PSA50 response rate and a 24% PSA90 rate with mostly Grade 1–2 adverse events, supporting its promise as a best-in-class PRC2 inhibitor in mCRPC (GlobeNewswire).
Raised $244 million in gross proceeds through a $125 million private placement and $119 million ATM issuance, extending available cash into the second half of 2028 and reducing near-term funding risk (GlobeNewswire).
Formed a clinical trial collaboration and supply agreement with Johnson & Johnson to test ORIC-114 in combination with subcutaneous amivantamab for first-line NSCLC, accelerating its path to registration (GlobeNewswire)).
Q2 2025 net loss increased to $36.4 million (EPS –$0.47 vs. –$0.44 consensus), highlighting persistently high cash burn with no revenue to offset it (Reuters).
Strategic pipeline prioritization resulted in a 20% reduction in workforce and the elimination of discovery research, focusing risk on just two lead programs since any failure in their registrational trials would have a major impact (GlobeNewswire).
ORIC shares have declined about 29.7% year-to-date, signaling investor skepticism in light of mixed clinical data and broader sector challenges (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $994M as of September 01, 2025.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of September 01, 2025.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of September 01, 2025.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.